A Multicenter, Open-label, Phase Ib/II Clinical Trial to Evaluate the Safety, Tolerance, Pharmacokinetics and Anti-tumor Efficacy of IN10018 Combined With Third-generation EGFR-TKI in Patients With Advanced EGFR Mutation-positive NSCLC
Latest Information Update: 21 Aug 2023
At a glance
- Drugs Firmonertinib (Primary) ; Ifebemtinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors InxMed
Most Recent Events
- 21 Aug 2023 New trial record